| 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer F Bensch, EL van der Veen, MN Lub-de Hooge, A Jorritsma-Smit, ... Nature medicine 24 (12), 1852-1858, 2018 | 632 | 2018 |
| Cardiovascular morbidity in long-term survivors of metastatic testicular cancer MT Meinardi, JA Gietema, WTA Van der Graaf, DJ Van Veldhuisen, ... Journal of Clinical Oncology 18 (8), 1725-1732, 2000 | 561 | 2000 |
| Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer AW van den Belt-Dusebout, R de Wit, JA Gietema, S Horenblas, ... Journal of Clinical Oncology 25 (28), 4370-4378, 2007 | 506 | 2007 |
| Metformin: taking away the candy for cancer? M Jalving, JA Gietema, JD Lefrandt, S de Jong, AKL Reyners, ROB Gans, ... European journal of cancer 46 (13), 2369-2380, 2010 | 487 | 2010 |
| Prognostic versus predictive value of biomarkers in oncology C Oldenhuis, SF Oosting, JA Gietema, EGE De Vries European journal of cancer 44 (7), 946-953, 2008 | 479 | 2008 |
| Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose … VAB van den Bogaard, BDP Ta, A van der Schaaf, AB Bouma, ... Journal of Clinical Oncology 35 (11), 1171-1178, 2017 | 470 | 2017 |
| Indium-111–labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer PJ Perik, MN Lub-De Hooge, JA Gietema, WTA van der Graaf, ... Journal of clinical oncology 24 (15), 2276-2282, 2006 | 445 | 2006 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 435 | 2020 |
| Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label … CN Sternberg, I Skoneczna, JM Kerst, P Albers, SD Fossa, M Agerbaek, ... The lancet oncology 16 (1), 76-86, 2015 | 417 | 2015 |
| Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer AW van den Belt-Dusebout, J Nuver, R de Wit, JA Gietema, ... Journal of clinical oncology 24 (3), 467-475, 2006 | 413 | 2006 |
| Cardiovascular toxicity caused by cancer treatment: strategies for early detection R Altena, PJ Perik, DJ Van Veldhuisen, EGE De Vries, JA Gietema The lancet oncology 10 (4), 391-399, 2009 | 359 | 2009 |
| Testicular cancer survivorship: research strategies and recommendations LB Travis, C Beard, JM Allan, AA Dahl, DR Feldman, J Oldenburg, ... Journal of the national cancer institute 102 (15), 1114-1130, 2010 | 328 | 2010 |
| Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer J Beyer, P Albers, R Altena, J Aparicio, C Bokemeyer, J Busch, ... Annals of oncology 24 (4), 878-888, 2013 | 325 | 2013 |
| ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up F Honecker, J Aparicio, D Berney, J Beyer, C Bokemeyer, R Cathomas, ... Annals of oncology 29 (8), 1658-1686, 2018 | 316 | 2018 |
| Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up HS Haugnes, GJ Bosl, H Boer, JA Gietema, M Brydøy, J Oldenburg, ... Journal of Clinical Oncology 30 (30), 3752-3763, 2012 | 308 | 2012 |
| A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week … F Eskens, CH Mom, AST Planting, JA Gietema, A Amelsberg, H Huisman, ... British journal of cancer 98 (1), 80-85, 2008 | 281 | 2008 |
| The metabolic syndrome in cancer survivors EC De Haas, SF Oosting, JD Lefrandt, BHR Wolffenbuttel, DT Sleijfer, ... The lancet oncology 11 (2), 193-203, 2010 | 273 | 2010 |
| The clinical trail of TRAIL EW Duiker, CH Mom, S De Jong, PHB Willemse, JA Gietema, ... European journal of cancer 42 (14), 2233-2240, 2006 | 252 | 2006 |
| Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients MT Meinardi, DJ Van Veldhuisen, JA Gietema, WV Dolsma, F Boomsma, ... Journal of Clinical Oncology 19 (10), 2746-2753, 2001 | 252 | 2001 |
| Predictors of adherence to exercise interventions during and after cancer treatment: a systematic review HL Ormel, GGF Van Der Schoot, WJ Sluiter, M Jalving, JA Gietema, ... Psycho‐oncology 27 (3), 713-724, 2018 | 250 | 2018 |
